FDA approves Cobenfy for adults with schizophrenia
The U.S. Food and Drug Administration has approved Bristol Myers Squibb's Cobenfy (xanomeline and trospium chloride), a first ...
Neuroscience News1d
Schizophrenia Risks Tied to Psychedelic Use
A new study links hallucinogen-related emergency department visits to a 21-fold increased risk of schizophrenia compared to ...
What Most People Get Wrong About Schizophrenia
The most common side effects of INVEGA HAFYERA® include: injection site reactions, weight gain, headache, upper respiratory ...
Medscape1d
Hallucinogens Tied to Striking Increased Risk of Schizophrenia Spectrum Disorder
ED visits related to hallucinogen use are linked to a 21-fold increased risk of schizophrenia spectrum disorder, results of a ...
clinicaladvisor.com1d
High MMP9 Predicts Poor Antipsychotic Treatment Response in Schizophrenia
Researchers conducted a cohort study to assess the predictive value of plasma MMP9 in antipsychotic treatment response among patients with schizophrenia.
AbbVie Provides Update on Phase 2 Results for Emraclidine in Schizophrenia
EMPOWER-1 and EMPOWER-2 Phase 2 clinical trials did not meet their primary endpoint Emraclidine was well-tolerated with an adverse event profile consistent with ...
Bristol's New Schizophrenia Drug Cobenfy Helps Support Its Wide Moat
More recent acquisitions in 2024—oncology firms Mirati and RayzeBio and neurology firm Karuna—also help support Bristol's strong overall pipeline and wide moat. Bristol has created a strong pipeline ...